Trends in Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States.

IF 7.5 1区 医学 Q1 SURGERY
Alexandra O Luby, Dominic Alessio-Bilowus, Hsou Mei Hu, Chad M Brummett, Jennifer F Waljee, Mark C Bicket
{"title":"Trends in Opioid Prescribing and New Persistent Opioid Use After Surgery in the United States.","authors":"Alexandra O Luby, Dominic Alessio-Bilowus, Hsou Mei Hu, Chad M Brummett, Jennifer F Waljee, Mark C Bicket","doi":"10.1097/SLA.0000000000006461","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To define recent trends in opioid prescribing after surgery and new persistent opioid use in the United States.</p><p><strong>Summary background data: </strong>New persistent opioid use after surgery among opioid-naïve individuals has emerged as an important postoperative complication. In response, initiatives to promote more appropriate post-operative opioid prescribing have been adopted in recent years. However, current estimates of opioid prescribing and new persistent opioid use following surgery remain unknown.</p><p><strong>Methods: </strong>A retrospective cohort study of opioid-naïve privately insured adult patients undergoing 17 common surgical procedures between 2013 and 2021 was conducted utilizing multi-payer claims data from the Health Care Cost Institute (HCCI). Initial opioid prescription size in oral morphine equivalents and new persistent opioid use were the outcomes of interest. Trends in opioid prescribing and rates of new persistent opioid use were evaluated across the study period. Mixed effects logistic regression was performed to evaluate independent predictors of new persistent opioid use while adjusting for patient-level factors and year.</p><p><strong>Results: </strong>Among 989,354 opioid-naïve individuals, the adjusted initial opioid prescription size decreased from 282 mg OME to 164 mg OME, a reduction of 118 mg OME (95% CI: 116-120). The adjusted incidence of new persistent opioid use decreased from 2.7% in 2013 (95% CI: 2.6%-2.8%) to 1.1% in 2021 (95% CI: 1.0%-1.2%). For every 30 OME increase in initial opioid prescription size, new persistent opioid use increased by 3.1%. Other predictors of new persistent opioid use included preoperative non-opioid controlled substances fills (31-365 days: aOR=1.78, 95% CI: 1.70-1.86; 0-30 days: aOR=2.71, 95% CI: 2.59-2.84) and undergoing orthopedic procedures (total knee arthroplasty (aOR=3.43, 95% CI: 3.15-3.72); shoulder arthroscopy (aOR=2.39, 95% CI: 2.24-2.56)).</p><p><strong>Conclusions: </strong>Both opioid prescription size after surgery and new persistent opioid use decreased over the last decade, suggesting that opioid stewardship practices had favorable effects on the risk of long-term opioid use.</p>","PeriodicalId":8017,"journal":{"name":"Annals of surgery","volume":null,"pages":null},"PeriodicalIF":7.5000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/SLA.0000000000006461","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"SURGERY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To define recent trends in opioid prescribing after surgery and new persistent opioid use in the United States.

Summary background data: New persistent opioid use after surgery among opioid-naïve individuals has emerged as an important postoperative complication. In response, initiatives to promote more appropriate post-operative opioid prescribing have been adopted in recent years. However, current estimates of opioid prescribing and new persistent opioid use following surgery remain unknown.

Methods: A retrospective cohort study of opioid-naïve privately insured adult patients undergoing 17 common surgical procedures between 2013 and 2021 was conducted utilizing multi-payer claims data from the Health Care Cost Institute (HCCI). Initial opioid prescription size in oral morphine equivalents and new persistent opioid use were the outcomes of interest. Trends in opioid prescribing and rates of new persistent opioid use were evaluated across the study period. Mixed effects logistic regression was performed to evaluate independent predictors of new persistent opioid use while adjusting for patient-level factors and year.

Results: Among 989,354 opioid-naïve individuals, the adjusted initial opioid prescription size decreased from 282 mg OME to 164 mg OME, a reduction of 118 mg OME (95% CI: 116-120). The adjusted incidence of new persistent opioid use decreased from 2.7% in 2013 (95% CI: 2.6%-2.8%) to 1.1% in 2021 (95% CI: 1.0%-1.2%). For every 30 OME increase in initial opioid prescription size, new persistent opioid use increased by 3.1%. Other predictors of new persistent opioid use included preoperative non-opioid controlled substances fills (31-365 days: aOR=1.78, 95% CI: 1.70-1.86; 0-30 days: aOR=2.71, 95% CI: 2.59-2.84) and undergoing orthopedic procedures (total knee arthroplasty (aOR=3.43, 95% CI: 3.15-3.72); shoulder arthroscopy (aOR=2.39, 95% CI: 2.24-2.56)).

Conclusions: Both opioid prescription size after surgery and new persistent opioid use decreased over the last decade, suggesting that opioid stewardship practices had favorable effects on the risk of long-term opioid use.

美国手术后阿片类药物处方和新的持续使用趋势。
目的确定美国术后阿片类药物处方和新的阿片类药物持续使用的最新趋势:阿片类药物过敏者术后新近持续使用阿片类药物已成为一种重要的术后并发症。为此,近年来采取了一些措施,以促进术后阿片类药物处方的更合理使用。然而,目前对阿片类药物处方和术后持续使用阿片类药物的估计仍不清楚:利用美国医疗费用研究所(HCCI)提供的多方付费者理赔数据,对 2013 年至 2021 年间接受 17 种常见外科手术、未使用过阿片类药物的私人投保成年患者进行了一项回顾性队列研究。以口服吗啡当量为单位的初始阿片类药物处方量和新的阿片类药物持续使用是研究的重点。在整个研究期间,对阿片类药物处方量和新的阿片类药物持续使用率的趋势进行了评估。在对患者层面的因素和年份进行调整的同时,还进行了混合效应逻辑回归,以评估新的阿片类药物持续使用的独立预测因素:在 989,354 名阿片类药物过敏者中,调整后的初始阿片类药物处方量从 282 毫克 OME 降至 164 毫克 OME,减少了 118 毫克 OME(95% CI:116-120)。调整后的阿片类药物新的持续使用率从2013年的2.7%(95% CI:2.6%-2.8%)下降到2021年的1.1%(95% CI:1.0%-1.2%)。阿片类药物初始处方量每增加 30 OME,新的阿片类药物持续使用率就会增加 3.1%。新的阿片类药物持续使用的其他预测因素包括术前非阿片类受控药物服用量(31-365 天:aOR=1.78,95% CI:1.70-1.86;0-30 天:aOR=2.71,95% CI:2.59-2.84)和接受矫形手术(全膝关节置换术(aOR=3.43,95% CI:3.15-3.72);肩关节镜检查(aOR=2.39,95% CI:2.24-2.56)):结论:在过去十年中,术后阿片类药物处方量和新的阿片类药物持续使用量均有所下降,这表明阿片类药物管理措施对长期使用阿片类药物的风险产生了有利影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of surgery
Annals of surgery 医学-外科
CiteScore
14.40
自引率
4.40%
发文量
687
审稿时长
4 months
期刊介绍: The Annals of Surgery is a renowned surgery journal, recognized globally for its extensive scholarly references. It serves as a valuable resource for the international medical community by disseminating knowledge regarding important developments in surgical science and practice. Surgeons regularly turn to the Annals of Surgery to stay updated on innovative practices and techniques. The journal also offers special editorial features such as "Advances in Surgical Technique," offering timely coverage of ongoing clinical issues. Additionally, the journal publishes monthly review articles that address the latest concerns in surgical practice.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信